Björn Niebel

As antibody-derived degraders emerge as a powerful alternative to small molecules, this workshop will teach you how to engineer and optimise these biologics to unlock new extracellular degradation strategies.

We will cover:

• Exploring the evolution of extracellular targeted protein degradation, from early conceptual approaches to emerging IgG-based degrader architectures
• Comparing antibody-based degraders with small-molecule strategies to assess modality selection, E3 engagement, and translational trade-offs
• Addressing key in vivo challenges, including biodistribution, internalisation, and tissue selectivity, to optimise therapeutic index and clinical potential

This workshop is ideal for scientists exploring how antibody-derived scaffolds can extend targeted protein degradation beyond intracellular targets.